Alpha Innotech has elected Joseph Keegan and Gus Davis to be independent directors on the company’s board of directors. Keegan formerly was CEO of Molecular Devices. Davis was chief operating officer of BioSource International, and he held senior posts at Amersham and Pharmacia Biotechnology.
Jerry Zemaitis, Stephen Donahue, Nathan Yoganathan, Bradley McLean, Joseph Keegan, Gus Davis
High Throughput Genomics has tapped Jerry Zemaitis to be vice president of commercial operations. In this new position, Zemaitis will handle strategic agreements and partnerships with businesses and with academic institutions.
Zemaitis previously was vice president of sales at SeraCare and was involved in business development at Caliper Technologies and at Aclara BioSciences. He most recently was founder of Zeta Strategic Consulting.
Gene Logic named Stephen Donahue to be president of its clinical development division. Donahue will run the company’s proprietary drug candidates through repositioning partnerships, the company said. Donahue formerly was vice president of clinical research and operations at Epix Pharmaceuticals and was medical director at Merck. He also was involved in clinical pharmaceutical development at Bristol-Meyers Squibb.
Nathan Yoganathan has shifted into a senior advisory role at Med BioGene. Yoganathan, the company’s founder and president, will quit his role as chief scientific officer to become chief scientific advisor.
Bradley McLean, a senior scientist at MBI, has been appointed to the newly opened chief scientific officer position. McLean has worked at Twinstrand Therapeutics and at InphoGene BioCommunications and was a post-doc fellow at the British Columbia Research Institute for Children’s and Women’s Health.